Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: A meta-analysis

Clinical Breast Cancer

Volumn 13, Issue 4, 2013, Pages 271-279

  Mghanga, Fabian Pius ^a   Lan, Xiaoli ^a   Bakari, Khamis Hassan ^a   Li, Chongjiao ^a   Zhang, Yongxue ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Breast cancer; Fluorine 18 fluorodeoxyglucose positron emission tomography; Meta analysis; Neoadjuvant chemotherapy; Therapy response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL EVALUATION; COCHRANE LIBRARY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DATA ANALYSIS SOFTWARE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EMBASE; HISTOPATHOLOGY; HUMAN; MEDLINE; META ANALYSIS; MINIMAL RESIDUAL DISEASE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; QUALITY CONTROL; RECEIVER OPERATING CHARACTERISTIC; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 84884704277     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.02.003     Document Type: Article

References (26)

1. Avril N, Sassen S, Roylance R. Response to therapy in breast cancer. J Nucl Med 2009;50(suppl 1):55S-63S.
2. Van Der Hage JA, Van De Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001;19:4224-37.
3. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188-94.
4. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006;243:257-64.
5. Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005;184:868-77.
6. Zhan S, Wang Z, Li LW, et al. Evaluation of early response to neoadjuvant chemotherapy in breast cancer patients by 18F-FDG and 99mTc-HL91 imaging. J Nucl Med Radiat Ther 2010;1:102.
7. Tiling R, Linke R, Untch M, et al. 18F-FDG PET and 99mTc-sestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med 2001;28:711-20.
8. Kim SJ, Kim SK, Lee ES, et al. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2004;15:1352-7.
9. Duch J, Fuster D, Muñoz M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging 2009;36:1551-7.
10. Dose-Schwarz J, Tiling R, Avril-Sassen S, et al. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. Br J Cancer 2010;102:35-41.
11. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using [(18) F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
12. Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 2006;24:5366-72.
13. McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughoutchemotherapyusingFDG-PET. Breast Cancer Res Treat 2007;102:75-84.
14. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18) F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88.
15. Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 2009;27:535-41.
16. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297-306.
17. Honkoop AH, Van Diest PJ, De Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998;77:621-6.
18. Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003;12:320-7.
19. Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007;34:1915-24.
20. Yuan Y, Chen XS, Liu SY, et al. Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis. AJR Am J Roentgenol 2010;195:260-8.
21. Tozaki M, Sakamoto M, Oyama Y, et al. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with (1) H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008;28:420-7.
22. Li D, Yao Q, Li L, et al. Correlation between hybrid 18F-FDG PET/CT and apoptosis induced by neoadjuvant chemotherapy in breast cancer. Cancer Biol Ther 2007;6:1442-8.
23. Kumar A, Kumar R, Seenu V, et al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol 2009;19:1347-57.
24. Schneider-Kolsky ME, Hart S, Fox J, et al. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. Breast Cancer Res 2010;12:R37.
25. Choi JH, Lim HI, Lee SK, et al. The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging. J Surg Oncol 2010;102:392-7.
26. Keam B, Im SA, Koh Y, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer 2011;11:452.